CN106619666A - Pharmaceutical composition for treating swine dysentery - Google Patents
Pharmaceutical composition for treating swine dysentery Download PDFInfo
- Publication number
- CN106619666A CN106619666A CN201611223297.3A CN201611223297A CN106619666A CN 106619666 A CN106619666 A CN 106619666A CN 201611223297 A CN201611223297 A CN 201611223297A CN 106619666 A CN106619666 A CN 106619666A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- swine dysentery
- evodin
- toosendanin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses pharmaceutical composition for treating swine dysentery. The pharmaceutical composition for treating the swine dysentery is prepared from main raw materials in parts by weight as follows; 5-16 parts of 9-nitro camptothecin, 2-6 parts of toosendanin, 9-10 parts of evodine, 25-32 parts of gomisin, 15-23 parts of topotecan hydrochloride, 2-4 parts of 11-keto-boswellic acid, 6-10 parts of methylophiopogonanone B, 0.5-1.4 parts of epoxylathyrol, 8-9 parts of isoforsythiaside and 2-4 parts of talatisamine. The components of raw materials of the medicine are strictly selected according to the knowledge mechanism of the swine dysentery, so that the purpose of comprehensive recovery is achieved, and the composition has the characteristics of taking effect quickly, acting stably, being convenient to carry and take and having no toxic and side effects after being taken for a long time.
Description
Technical field
The present invention relates to a kind of field of medicine preparation, specifically a kind of pharmaceutical composition for treating swine dysentery.
Background technology
Swine dysentery is called pig blood dysentery, is a kind of serious enteric infectious disease caused by Treponema Hyodysenteriae, mainly faces
It is serious mucus hemorrhagic diarrhea to examine symptom, and acute is subacute and chronic with mucus abdomen based on hemorrhagic diarrhea
Rush down by a definite date based on.Cut open inspection pathological characters are that colorectal mucosa occurs Catarrhal, hemorrhagic and gangrenous inflammation.In the case of nature,
Only pig morbidity, various ages, the pig of kind all can infect, but mainly what is encroached on is the piglet at 2-3 monthly ages；The incidence of disease of piggy
It is all high than big pig with the death rate；Sick pig and carrier are main source of infection, and the generation of this disease is without obvious seasonality；Due to band
The presence of bacterium pig, transfers frequently by swinery and buys and sells pig and disease is scattered.Carry disease germs pig, under normal feeding and management condition often
Do not fall ill, when having the unfavorable factor for reducing pig body resistance, raising deficiency, be deficient in vitamin with stress factor, just can promote
Cause morbidity.Sick pig is treated in time, drug therapy, often there is certain effect, and such as LIJUNJING (dislike by MAQO, 3- methyl-acetyl group-quinoline
Woods-Isosorbide-5-Nitrae-dioxide) 5mg/kg, take orally, 2 times a day, and it is a course for the treatment of to serve on 3, or by 0.5% LIJUNJING solution 0.5ml/
Kg, intramuscular injection；Various antibacterials such as diformazan nitro miaow pyridine, neomycinsulphate, furazolidone, lincomycin, Cyclomycin family antibiotic
Medicine has certain curative effect.Although this drug therapy has certain effect, but the problem brought is that antibiotic residual quantity is high.
Antibiotic may enter human body with pork, easily produce antibiotic resistance to human body.Therefore we need to find a kind of
This kind of disease of new drug therapy.
The content of the invention
It is an object of the invention to provide a kind of pharmaceutical composition for treating swine dysentery, to solve above-mentioned background technology in carry
The problem for going out.
For achieving the above object, the present invention provides following technical scheme：
A kind of pharmaceutical composition for treating swine dysentery, be according to the primary raw material of weight portion：9-nitrocamptothecin 5-16 parts,
Toosendanin 2-6 parts, evodin 9-10 parts, Gomisin G 25-32 parts, topotecan hydrochloride 15-23 parts, 11- ketone group frankincenses
Sour 2-4 parts, methyl ophiopogon flavonoid B 6-10 parts, epoxylathyrol 0.5-1.4 parts, different capsule of weeping forsythia fat glycosides 8-9 parts, tower draw the rhizome of Chinese monkshood
Amine 2-4 parts.
As further scheme of the invention：The pharmaceutical composition of the treatment swine dysentery, according to the main original of weight portion
Expect be：9-nitrocamptothecin 8-12 parts, toosendanin 3-5 parts, evodin 9-10 parts, Gomisin G 28-30 parts, hydrochloric acid topology
For health 18-21 part, 11- ketone group masticinic acid 2-4 parts, methyl ophiopogon flavonoid B 6-10 parts, epoxylathyrol 0.5-1.4 parts,
Different capsule of weeping forsythia fat glycosides 8-9 parts, talastisamine 2-4 parts.
As further scheme of the invention：The pharmaceutical composition of the treatment swine dysentery, according to the main original of weight portion
Expect be：10 parts of 9-nitrocamptothecin, 4 parts of toosendanin, 10 parts of evodin, 29 parts of Gomisin G, 19 parts of topotecan hydrochloride,
3 parts of 11- ketone groups masticinic acid, 8 parts of methyl ophiopogon flavonoid B, 0.9 part of epoxylathyrol, different 9 parts of capsule of weeping forsythia fat glycosides, Ta Lawu
3 parts of amine of head.
A kind of preparation method of the pharmaceutical composition for treating swine dysentery, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh 9-nitrocamptothecin, toosendanin, evodin,
Gomisin G, topotecan hydrochloride, 11- ketone group masticinic acids, methyl ophiopogon flavonoid B, epoxylathyrol, different capsule of weeping forsythia fat glycosides,
Talastisamine, sieves, and machinery adds ultra-pure water after mixing, in placing pharmacy mixer, mixing 4-8min, control RSD≤
5%, compressing tablet and low temperature drying after mixing, at 4-8 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of swine dysentery to temperature control.
As further scheme of the invention：Mix 6min in concrete steps.
Compared with prior art, the invention has the beneficial effects as follows：
Medicine of the present invention is strictly selected material composition according to the understanding mechanism of swine dysentery, so as to reach comprehensive rehabilitation
Purpose, with rapid-action, effect it is stable, carry taking convenience, long-term taking and have no toxic side effect the characteristics of.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than the embodiment of whole.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
A kind of pharmaceutical composition for treating swine dysentery, be according to the primary raw material of weight portion：5 parts of 9-nitrocamptothecin, river
2 parts of chinaberry element, 9 parts of evodin, 25 parts of Gomisin G, 15 parts of topotecan hydrochloride, 2 parts of 11- ketone groups masticinic acid, methyl wheat
6 parts of winter flavanones B, 0.5 part of epoxylathyrol, different 8 parts of capsule of weeping forsythia fat glycosides, 2 parts of talastisamine.
A kind of preparation method of the pharmaceutical composition for treating swine dysentery, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh 9-nitrocamptothecin, toosendanin, evodin,
Gomisin G, topotecan hydrochloride, 11- ketone group masticinic acids, methyl ophiopogon flavonoid B, epoxylathyrol, different capsule of weeping forsythia fat glycosides,
Talastisamine, sieves, and machinery adds ultra-pure water after mixing, and in placing pharmacy mixer, mixes 4min, controls RSD≤5%,
Compressing tablet and low temperature drying after mixing, at 4 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of swine dysentery to temperature control.
Embodiment 2
A kind of pharmaceutical composition for treating swine dysentery, be according to the primary raw material of weight portion：8 parts of 9-nitrocamptothecin, river
3 parts of chinaberry element, 9 parts of evodin, 28 parts of Gomisin G, 18 parts of topotecan hydrochloride, 2 parts of 11- ketone groups masticinic acid, methyl wheat
6 parts of winter flavanones B, 0.5 part of epoxylathyrol, different 8 parts of capsule of weeping forsythia fat glycosides, 2 parts of talastisamine.
A kind of preparation method of the pharmaceutical composition for treating swine dysentery, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh 9-nitrocamptothecin, toosendanin, evodin,
Gomisin G, topotecan hydrochloride, 11- ketone group masticinic acids, methyl ophiopogon flavonoid B, epoxylathyrol, different capsule of weeping forsythia fat glycosides,
Talastisamine, sieves, and machinery adds ultra-pure water after mixing, and in placing pharmacy mixer, mixes 4min, controls RSD≤5%,
Compressing tablet and low temperature drying after mixing, at 4 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of swine dysentery to temperature control.
Embodiment 3
A kind of pharmaceutical composition for treating swine dysentery, be according to the primary raw material of weight portion：10 parts of 9-nitrocamptothecin, river
4 parts of chinaberry element, 10 parts of evodin, 29 parts of Gomisin G, 19 parts of topotecan hydrochloride, 3 parts of 11- ketone groups masticinic acid, methyl wheat
8 parts of winter flavanones B, 0.9 part of epoxylathyrol, different 9 parts of capsule of weeping forsythia fat glycosides, 3 parts of talastisamine.
A kind of preparation method of the pharmaceutical composition for treating swine dysentery, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh 9-nitrocamptothecin, toosendanin, evodin,
Gomisin G, topotecan hydrochloride, 11- ketone group masticinic acids, methyl ophiopogon flavonoid B, epoxylathyrol, different capsule of weeping forsythia fat glycosides,
Talastisamine, sieves, and machinery adds ultra-pure water after mixing, and in placing pharmacy mixer, mixes 6min, controls RSD≤5%,
Compressing tablet and low temperature drying after mixing, at 6 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of swine dysentery to temperature control.
Embodiment 4
A kind of pharmaceutical composition for treating swine dysentery, be according to the primary raw material of weight portion：12 parts of 9-nitrocamptothecin, river
5 parts of chinaberry element, 10 parts of evodin, 30 parts of Gomisin G, 21 parts of topotecan hydrochloride, 4 parts of 11- ketone groups masticinic acid, methyl wheat
10 parts of winter flavanones B, 1.4 parts of epoxylathyrol, different 9 parts of capsule of weeping forsythia fat glycosides, 4 parts of talastisamine.
A kind of preparation method of the pharmaceutical composition for treating swine dysentery, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh 9-nitrocamptothecin, toosendanin, evodin,
Gomisin G, topotecan hydrochloride, 11- ketone group masticinic acids, methyl ophiopogon flavonoid B, epoxylathyrol, different capsule of weeping forsythia fat glycosides,
Talastisamine, sieves, and machinery adds ultra-pure water after mixing, and in placing pharmacy mixer, mixes 8min, controls RSD≤5%,
Compressing tablet and low temperature drying after mixing, at 8 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of swine dysentery to temperature control.
Embodiment 5
A kind of pharmaceutical composition for treating swine dysentery, be according to the primary raw material of weight portion：16 parts of 9-nitrocamptothecin, river
6 parts of chinaberry element, 10 parts of evodin, 32 parts of Gomisin G, 23 parts of topotecan hydrochloride, 4 parts of 11- ketone groups masticinic acid, methyl wheat
10 parts of winter flavanones B, 1.4 parts of epoxylathyrol, different 9 parts of capsule of weeping forsythia fat glycosides, 4 parts of talastisamine.
A kind of preparation method of the pharmaceutical composition for treating swine dysentery, concretely comprises the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh 9-nitrocamptothecin, toosendanin, evodin,
Gomisin G, topotecan hydrochloride, 11- ketone group masticinic acids, methyl ophiopogon flavonoid B, epoxylathyrol, different capsule of weeping forsythia fat glycosides,
Talastisamine, sieves, and machinery adds ultra-pure water after mixing, and in placing pharmacy mixer, mixes 8min, controls RSD≤5%,
Compressing tablet and low temperature drying after mixing, at 8 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of swine dysentery to temperature control.
Pharmacology test
1st, chronic toxicity test
With pharmaceutical composition obtained in the embodiment of the present invention 3 as test, using gastric infusion mode, continuously give in 24h
Medicine 2 times, per minor tick 8h, is administered every time 300mg/kg doses, and daily accumulation medicine total amount reaches 600mg medicines/kg, equivalent to pig
100 times of quantity.After administration in 7d, mouse activity, feed, excretion are normal, well-grown, hair color light, and its is average
Body weight increases with the prolongation of experimental period.Every mouse of post mortem at 8d, visually observe the heart, liver, spleen, lung, kidney,
Brain, thymus gland, stomach, intestines etc. do not find color and paramophia, fail to measure median lethal dose (LD50).As a result show：This
Bright pharmaceutical composition is without chronic toxicity.
2nd, long term toxicity test
With pharmaceutical composition obtained in the embodiment of the present invention 3 as test, using gastric infusion mode, by medicine group of the present invention
Compound is divided into low dosage, middle dosage, three groups of high dose, the drug dose of each group is respectively 60,120,180mg medicines/kg/d, phase
When in 10,20,30 times of clinical dosage.After gastric infusion 24 weeks, medicine of the present invention refers to the general status of animal, hematology
Mark, blood parameters without significantly impact, Systematic anatomy, organ coefficient and histopathological examination also no abnormal disease
Reason changes.It is discontinued 2 weeks and also has no substantially change.As a result show：Pharmaceutical composition of the present invention does not find in long term toxicity test
Overt toxicity reacts and delayed toxicity reaction.It can be seen that, pharmaceutical composition non-toxic reaction of the present invention, long-term prescription is safe and reliable.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of spirit or essential attributes without departing substantially from the present invention, the present invention can be in other specific forms realized.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit is required rather than described above is limited, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although this specification is been described by according to embodiment, not each embodiment is only wrapped
Containing an independent technical scheme, this narrating mode of specification is only that for clarity those skilled in the art should
Using specification as an entirety, the technical scheme in each embodiment can also Jing it is appropriately combined, form those skilled in the art
Understandable other embodiment.
Claims (5)
1. a kind of pharmaceutical composition for treating swine dysentery, it is characterised in that the primary raw material according to weight portion is：9- nitro camplotheca acuminatas
Alkali 5-16 parts, toosendanin 2-6 parts, evodin 9-10 parts, Gomisin G 25-32 parts, topotecan hydrochloride 15-23 parts,
11- ketone group masticinic acid 2-4 parts, methyl ophiopogon flavonoid B 6-10 parts, epoxylathyrol 0.5-1.4 parts, different capsule of weeping forsythia fat glycosides 8-
9 parts, talastisamine 2-4 parts.
2. it is according to claim 1 treatment swine dysentery pharmaceutical composition, it is characterised in that the medicine of the treatment swine dysentery
Compositions, be according to the primary raw material of weight portion：9-nitrocamptothecin 8-12 parts, toosendanin 3-5 parts, evodin 9-10
Part, Gomisin G 28-30 parts, topotecan hydrochloride 18-21 parts, 11- ketone group masticinic acid 2-4 parts, methyl ophiopogon flavonoid B 6-
10 parts, epoxylathyrol 0.5-1.4 parts, different capsule of weeping forsythia fat glycosides 8-9 parts, talastisamine 2-4 parts.
3. it is according to claim 1 and 2 treatment swine dysentery pharmaceutical composition, it is characterised in that the treatment swine dysentery
Pharmaceutical composition, be according to the primary raw material of weight portion：10 parts of 9-nitrocamptothecin, 4 parts of toosendanin, evodin 10
Part, 29 parts of Gomisin G, 19 parts of topotecan hydrochloride, 3 parts of 11- ketone groups masticinic acid, 8 parts of methyl ophiopogon flavonoid B, epoxy continue
With 0.9 part of sub- alcohol, different 9 parts of capsule of weeping forsythia fat glycosides, 3 parts of talastisamine.
4. a kind of preparation method of the pharmaceutical composition of the treatment swine dysentery as described in claim 1-3 is arbitrary, it is characterised in that
Concretely comprise the following steps：
First, in pharmaceutical grade clean area, 9-nitrocamptothecin, toosendanin, evodin, dagger-axe rice are weighed by above-mentioned metering ratio
Pungent G, topotecan hydrochloride, 11- ketone group masticinic acids, methyl ophiopogon flavonoid B, epoxylathyrol, different capsule of weeping forsythia fat glycosides, tower draw
Aconine, sieves, and machinery adds ultra-pure water after mixing, and in placing pharmacy mixer, mixes 4-8min, controls RSD≤5%, mixes
Compressing tablet and low temperature drying after conjunction, at 4-8 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of swine dysentery to temperature control.
5. it is according to claim 4 treatment swine dysentery pharmaceutical composition preparation method, it is characterised in that concrete steps
Middle mixing 6min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611223297.3A CN106619666A (en) | 2016-12-27 | 2016-12-27 | Pharmaceutical composition for treating swine dysentery |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611223297.3A CN106619666A (en) | 2016-12-27 | 2016-12-27 | Pharmaceutical composition for treating swine dysentery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106619666A true CN106619666A (en) | 2017-05-10 |
Family
ID=58831434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611223297.3A Pending CN106619666A (en) | 2016-12-27 | 2016-12-27 | Pharmaceutical composition for treating swine dysentery |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106619666A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107875149A (en) * | 2017-11-19 | 2018-04-06 | 郑士平 | It is a kind of treat drug-resistant bacteria caused by urinary tract infections transdermal absorption formulation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101775058A (en) * | 2009-01-08 | 2010-07-14 | 凌沛学 | Preparation and application of pharmaceutic preparation of 11-carbonyl-betal- acetyl mastic acid and derivatives thereof extracted from frankincense |
-
2016
- 2016-12-27 CN CN201611223297.3A patent/CN106619666A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101775058A (en) * | 2009-01-08 | 2010-07-14 | 凌沛学 | Preparation and application of pharmaceutic preparation of 11-carbonyl-betal- acetyl mastic acid and derivatives thereof extracted from frankincense |
Non-Patent Citations (3)
| Title |
|---|
| 佟昕 等: "乳香质量标准的研究", 《中华中医药学会中药炮制分会2011年学术年会论文集》 * |
| 孟祥乐 等: "连翘的化学成分及其药理活性研究进展", 《中国药房》 * |
| 杨志欣 等: "吴茱萸化学拆分组分的性味药理学评价——化学拆分组分止泻、止吐作用的研究", 《中医药学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107875149A (en) * | 2017-11-19 | 2018-04-06 | 郑士平 | It is a kind of treat drug-resistant bacteria caused by urinary tract infections transdermal absorption formulation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102488746B (en) | Compound propolis composition for treating swine infectious atrophic rhinitis and preparation method thereof | |
| CN106619666A (en) | Pharmaceutical composition for treating swine dysentery | |
| CN106727591A (en) | A kind of pharmaceutical composition for treating Streptococcus suis | |
| CN102727693B (en) | Compound propolis composition used for treating swine toxoplasmosis, and preparation method thereof | |
| CN106580948A (en) | Pharmaceutical composition for treating swine dysentery | |
| CN104288268A (en) | Traditional Chinese medicinal formula for preventing and treating common diseases of chicken | |
| CN103536482B (en) | Compound Chinese medicine extract is as sole active agent application in preparation oral cavity product | |
| CN106727642A (en) | A kind of children's antipyretic | |
| CN106511440A (en) | Compound Chinese and Western medicine composition for treating chronic dysentery and preparation method thereof | |
| CN104622708A (en) | Application of geniposide in preparation of oral care health products | |
| CN106727907A (en) | A kind of Chinese and Western medicine combination for treating viral pneumonia and preparation method thereof | |
| CN106619874A (en) | Drug composition used for treating swine dysentery | |
| CN106822239A (en) | It is a kind of to treat Chinese and western medicinal composition of the infection of the upper respiratory tract and preparation method thereof | |
| CN106511665A (en) | Pharmaceutical for treating allergic pneumonia | |
| CN103055002A (en) | Composition for treating respiratory disease of poultry and preparation method thereof | |
| CN106619682A (en) | Pharmaceutical composition for treating porcine diarrhea | |
| CN106619672A (en) | Western medicine for treating adult ascariasis | |
| CN106727494A (en) | A kind of Western medicine for treating Eaton agent pneumonia | |
| CN106727786A (en) | A kind of antipyretic of children's Integrated TCM and preparation method thereof | |
| CN106619890A (en) | Chinese and Western medicine composition for treating ascariasis and preparation method thereof | |
| CN106822133A (en) | A kind of Western medicine compound for treating acute diarrhea | |
| CN106620642A (en) | Western medicine composition for treating hyperglycemia | |
| CN106581031A (en) | Compound Western medicine for treating pertussis | |
| CN106727508A (en) | A kind of combination drug for treating chronic dysentery | |
| CN106668140A (en) | Chinese and western medicine composition for treating porcine diarrhea and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170510 |
|
| RJ01 | Rejection of invention patent application after publication |